title: Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
abstract: OBJECTIVE
  The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation of progression-free survival (PFS) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation. Since only a few patients with non-adenocarcinoma histology have been enrolled in clinical trials, the efficacy of EGFR TKIs in non-adenocarcinoma NSCLC patients with EGFR mutation has not yet been fully determined.
  
  
  METHODS
  We retrospectively analyzed clinical outcomes, including RR, PFS, and OS, in patients who were treated with the EGFR TKIs gefitinib or erlotinib and compared the results with those of adenocarcinoma patients with EGFR mutation and non-adenocarcinoma patients with wild-type EGFR.
  
  
  RESULTS
  Among 250 patients with non-adenocarcinoma of the lung who underwent EGFR mutation genotyping, 21 were found to have an EGFR mutation (8.4 %). Twelve of the 21 patients were treated with the EGFR TKIs gefitinib (n = 6) or erlotinib (n = 6). The most common mutation was exon 19 deletion (n = 7). The RR and disease control rate for 12 patients receiving EGFR TKIs were 50 and 75 %, respectively. The median PFS was 3.67 months (95 % CI: 1.34-5.99), which was significantly lower than that of 269 adenocarcinoma patients with EGFR mutation (13.53 months) but better than that of 32 non-adenocarcinoma patients with wild-type EGFR (1.83 months) who were treated with EGFR TKIs.
  
  
  CONCLUSIONS
  The results of this study show that the EGFR mutation rate in Korean patients with non-adenocarcinoma of the lung is relatively high and that the clinical outcomes of EGFR TKIs are modest.
authors: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea.
authors: Su-Hee
authors: SH
authors: Cho
authors: Lee Chun
authors: LC
authors: Park
authors: Jun Ho
authors: JH
authors: Ji
authors: Silvia
authors: S
authors: Park
authors: Deok Won
authors: DW
authors: Hwang
authors: Ji Yean
authors: JY
authors: Lee
authors: Yoon-La
authors: YL
authors: Choi
authors: Jung-Ho
authors: JH
authors: Han
authors: Jong-Mu
authors: JM
authors: Sun
authors: Jin Seok
authors: JS
authors: Ahn
authors: Keunchil
authors: K
authors: Park
authors: Myung-Ju
authors: MJ
authors: Ahn
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use; D056910:Republic of Korea; D012189:Retrospective Studies
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib